Evogene Ltd - ADR

Name: Evogene Ltd - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Evogene Ltd - ADR

Stock Card

$0.55

$0.01 (2.20%)

As on 28-Aug-2026 13:09EDT

Market cap

$9 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

P/B Ratio

6.2

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Evogene - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.54 High: 0.56

52 Week Range

Low: 0.37 High: 1.50

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.7 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.8
Debt to Equity

0
Book Value

$--
EPS

$-0.9
Face value

--
Shares outstanding

15,801,407

10 Years Aggregate

CFO

$-171.06 Mln

EBITDA

$-192.10 Mln

Net Profit

$-222.47 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Evogene - ADR	-50.0	5.7	-22.6	-58.0	-57.5	-54.3	-38.4
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021	2020	2019
Evogene - ADR	-41.2	20.0	-57.3	-65.1	209.2	-23.2
S&P Small-Cap 600	4.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Evogene - ADR	0.5	8.9	1.3	-9.1	-1,029.8	--	--	6.2
Compugen - ADR	2.6	247.7	74.0	35.2	0.0	36.8	7.1	2.8
Galmed Pharmaceuticals - ADR	4.1	4.5	0.0	-13.4	--	-90.4	--	0.3
Sol-Gel Technologies - ADR	68.6	254.1	1.8	-16.3	0.0	-46.1	--	5.2
UroGen Pharma (URGN)	43.7	2,290.5	188.7	-97.6	-38.6	--	--	19.3

Shareholding Pattern

View Details

About Evogene - ADR

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company... engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel. Read more

CEO & President

Mr. Ofer Haviv CPA
CEO & President

Mr. Ofer Haviv CPA
Headquarters

Rehovot
Website

https://www.evogene.com

FAQs for Evogene - ADR

What is the current share price of Evogene Ltd - ADR Today?

The share price of Evogene Ltd - ADR is $0.55 (NASDAQ) as of 28-Aug-2026 13:09 EDT. Evogene Ltd - ADR has given a return of -57.5% in the last 3 years.

What is the current PB & PE ratio of Evogene Ltd - ADR?

Since, TTM earnings of Evogene Ltd - ADR is negative, P/E ratio is not available.
The P/B ratio of Evogene Ltd - ADR is 6.18 times as on 21-Aug-2026, a 118 premium to its peers’ median range of 2.84 times.

PE & PB ratio at the end of financial year.